KWM
ATOS icon

Kingsview Wealth Management’s Atossa Therapeutics ATOS Stock Holding History

Kingsview Wealth Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-194
Closed -$16K – 384
2018
Q1 		$16K Sell
194
-117
-38% -$10.9K ﹤0.01% 309
2017
Q4 		$15K Buy
+311
New +$22.6K 0.01% 317

Other funds holding ATOS

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kingsview Wealth Management's ATOS Position: Q2 2018 in Review

Kingsview Wealth Management sold out of Atossa Therapeutics (ATOS) in Q2 2018, closing a stake of 194 shares — an estimated $16K sold.

Kingsview Wealth Management first reported a position in ATOS in Q4 2017 and held it in 2 quarters. The position peaked at $16K in Q1 2018. 14 funds tracked by Wall St. Rank hold ATOS as of Q2 2018.

  • Kingsview Wealth Management reported no remaining Atossa Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Kingsview Wealth Management sold 194 Atossa Therapeutics shares in Q2 2018, an estimated $16K.
  • Kingsview Wealth Management first reported a position in Atossa Therapeutics in Q4 2017 and held it in 2 quarters.
  • Kingsview Wealth Management's Atossa Therapeutics position peaked at $16K in Q1 2018.
  • 14 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2018.

Based on Kingsview Wealth Management's 13F filing for Q2 2018, filed 29 Jan 2020.